Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04GAX
|
|||
| Former ID |
DNC014112
|
|||
| Drug Name |
3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate
|
|||
| Synonyms |
CHEMBL576381; 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate; SCHEMBL4751773
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H16N2O3
|
|||
| Canonical SMILES |
CCCNC(=O)OC1=CC=CC(=C1)C2=NCCO2
|
|||
| InChI |
1S/C13H16N2O3/c1-2-6-15-13(16)18-11-5-3-4-10(9-11)12-14-7-8-17-12/h3-5,9H,2,6-8H2,1H3,(H,15,16)
|
|||
| InChIKey |
JLCYRBIRENXOKD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.